STORYLINE
Injectable HIV medicines deal to provide access to generic lifesaver in developing nations
A landmark agreement has been reached allowing for the production of low-cost, injectable HIV medicines in some 90 developing countries where more the majority of infections occur, UNITAID said on Friday.
Selected manufacturers will be able to develop, manufacture and supply lower-cost generic versions of long-acting Cabotegravir (CAB-LA), in line with a deal reached with pharmaceutical firm ViiV Healthcare (ViiV).
“The Medicines Patent Pool, a structure created and largely funded by UNITAID, has reached a voluntary licensing agreement for patents relating to Cabotegravir long-acting, an injectable form of HIV prevention, or PrEP, to generic formulations of the product in least-developed, low-income, lower-middle income and sub-Saharan African countries,” said UNITAID spokesperson Hervé Verhoosel.
The deal is significant because Cabotegravir injections are only needed once every few months. Increasing its supply at a cost that is affordable to low-income countries could help to overcome the stigma that’s associated with taking daily HIV pills - and the burden of having to remember to take them.
“In the 90 countries that we are talking about, 80 countries are royalty-free, meaning that ViiV won’t ask for any royalty on the product and for 10 of those countries, ViiV is asking for a smaller-than-usual royalty,” Mr. Verhoosel explained.
The agreement comes after UNITAID-led discussions began in May this year with ViiV, a subsidiary of pharma giant GlaxoSmithkline. It is only seven months since Cabotegravir LA received regulatory approval.
But the process of selecting the companies that will develop, manufacture and supply generic versions of Cabotegravir will take much longer.
“This product will not be there for everybody, that’s first for people who are there the most at risk,” said Mr. Verhoosel, who noted that the cost of the medicine in the US when it comes onstream there “really soon”, was likely to be around $20,000. “That’s a lot of money; that’s why that product cannot be used in low and middle-income countries.”
According to UNITAID, the deal offers the possibility of making the injectable prophylactic medicine available in 90 countries where more than 70 per cent of all new HIV infections occurred in 2020.
Up to three drug manufacturers will be licensed to develop the product on a generic basis to avoid supply and distribution issues. “That’s done in a way that we’re sure (that) one, it’s easy for logistics, two…availability, and three, of course, that it will help to bring the cost of the generic version down”, said Mr. Verhoosel.
ends
STORY: Injectable HIV Prevention Medicines Deal - UNITAID
TRT: 02’05”
SOURCE: UNTV CH
RESTRICTIONS: NONE
LANGUAGE: ENGLISH/NATS
ASPECT RATIO: 16:9
DATELINE: Friday 29 July 2022, GENEVA, SWITZERLAND
SHOTLIST
2
1
2
Edited News , Press Conferences | UNRWA
UNRWA Commissioner-General Philippe Lazzarini will update the press on the situation in the Occupied Palestinian Territory.
1
1
1
Edited News | WHO
Summary: WHO deems current public health risk posed by avian influenza A (H5N1) low. Virus detected in calves and dairy cattle in the U.S., but virus fragments in pasteurized milk are not infectious. Surveillance and information sharing are crucial in combating the spread of zoonotic viruses.
1
1
1
Edited News | UNMAS
The head of UN peacekeeping and demining reiterated calls on Monday for a ceasefire in Gaza on Monday as a first step to returning the war-ravaged enclave to some normality, while mine clearance experts warned that Gaza is now at its “most dangerous period”.
1
1
1
Edited News | OHCHR , UNOG
UN High Commissioner for Human Rights Volker Türk is gravely concerned by the escalating violence in and around El-Fasher city, North Darfur, where dozens of people have been killed in the past two weeks as hostilities between the Sudanese Armed Forces (SAF) and the Rapid Support Forces (RSF) have intensified., UN Human Rights spokesperson Seif Magango told the biweekly press briefing in Geneva.
1
1
1
Edited News | OHCHR , UNOG
At the bi-weekly press conference in Geneva Jeremy Laurence, Spokesperson for the UN Human Rights Office (OHCHR) briefed the journalist on the latest development in Iran.
1
1
1
Edited News | WHO
"WHO warns of widespread misuse of antibiotics during COVID-19 pandemic, fueling antimicrobial resistance."